Summit Therapeutics (SMMT, Financial) continues to garner attention in the investment community as HC Wainwright & Co. reiterated its 'Buy' rating for the company. The stock's price target remains unchanged at $44.00 USD, as reported on July 1, 2025.
Analyst Mitchell Kapoor from HC Wainwright & Co. confirmed the consistent price target, which shows confidence in the stock's valuation and potential. The price target matched the previous figure, indicating stable outlooks for Summit Therapeutics (SMMT, Financial).
Investors are assessing these developments keenly, with the 'Buy' recommendation underscoring expectations of positive performance for Summit Therapeutics (SMMT, Financial) in the market. The unchanged price target highlights the analyst's sustained confidence in the company's growth trajectory.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 10 analysts, the average target price for Summit Therapeutics Inc (SMMT, Financial) is $31.60 with a high estimate of $44.00 and a low estimate of $5.00. The average target implies an upside of 48.43% from the current price of $21.29. More detailed estimate data can be found on the Summit Therapeutics Inc (SMMT) Forecast page.
Based on the consensus recommendation from 12 brokerage firms, Summit Therapeutics Inc's (SMMT, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
